Clearside Biomedical Inc at UBS Global Healthcare Conference Transcript
(technical difficulty)
To the UBS Healthcare Conference. My name is [Andrew Dorskind]. I'll be your host for this session. Now it's my pleasure to introduce Brion Raymond, the Chief Commercial Officer, from Clearside Biomedical. And just note that immediately following the presentation, there will be a breakout session in the [Juilliard] Room.
Thank you, Andrew. Thank you, and good morning. Clearside Biomedical is dedicated to treating vision-threatening diseases in the back of eye through our proprietary technology that allows us to access the suprachoroidal space.
The combination of the suprachoroidal space, our proprietary microinjector and both novel and existing therapies allows us to bring new therapies and new clinical profiles to both existing and new drugs. And our lead product, XIPERE, is currently sitting in the FDA under review with an October PDUFA date or a PDUFA date of October 2019. The suprachoroidal injection platform really is a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
